1992


Company establishment


1995

5 μg/0.5ml/standard hepatitis B vaccine meets Merck's quality standards



Obtaining the Ministry of Health trial production approval number


1998


Obtained the official approval number from the State Food and Drug Administration


2000


Hepatitis B vaccine passed GMP certification for the first time


2002


Successfully Developed 10 μg/1.0ml/Standard Hepatitis B Vaccine for Adults


2004


Successfully developed the first three-year hepatitis B vaccine in China


2005

Add 10μg/0.5ml/piece of standard hepatitis B vaccine for adults, replacing 10μg/1.0ml/piece size


Hepatitis B vaccine passed GMP certification for the second time


2008


After the strategic reorganization, Beijing Minhai Biotechnology Co., Ltd. became a wholly-owned subsidiary of Kangtai Biotechnology


2010

First domestically developed 60μg/1.0ml/counter hepatitis B vaccine for adult non-response population


Hepatitis B vaccine passed GMP certification for the third time

2011

Successfully developed adult 20μg/1.0ml/support hepatitis B vaccine


Successfully developed 10g/0.5ml/standard hepatitis B vaccine for children


2012

Haemophilus influenzae type b conjugate vaccine passed GMP certification


Acellular Baidubai Haemophilus influenzae combined vaccine passed GMP certification


2013


Measles Rubella Combined with Live Attenuated Vaccine Passes GMP Certification


2014

Hepatitis B vaccine passed the 2010 version of GMP certification


Haemophilus influenzae type b conjugate vaccine (pre-filled) passed GMP certification


2017


The company is listed on the GEM of Shenzhen Stock Exchange, stock code 300601


2018


In October,Kangtai Guangming base was officially put into use


2019


23-Valent Pneumonia Vaccine received lot release and was officially launched into market


2020


Start construction of COVID-19 inactivated vaccine production workshop in Nanshan district,Shenzhen;

Signs deal with AstraZeneca on development and industrialization of a COVID-19 vaccine based on adenovirus vector